Organisation: Novartis

Europe’s biggest demerger; a portfolio of well-loved brands; fighting threats to consumer health: all in a year’s work at Haleon

Sophie Bodet, vice president – head of intellectual property at Haleon, reveals the pivotal role her team played in Europe’s biggest demerger of the past 20 years – all while managing a portfolio of 33,000 trademarks covering some of healthcare’s best-known brands.

07 August 2023

Revealed: the biggest portfolios in Asia-Pacific

We scrutinise the data to reveal the 50 companies with the largest portfolios in five major jurisdictions.

13 July 2023

Emergent tech and electric cars shake up brand landscape

Virtual headsets, electric cars and NFT art make their presence known in Clarivate's 2023 Top 100 New Brands report.

29 June 2023

Legal Updates you may have missed: when the EUIPO Board of Appeal gets it wrong

Each quarter WTR runs a series of pieces highlighting recent Legal Updates that you may have missed. We kick off this new series by looking at cases where the EUIPO was rebuked by the General Court for reaching an erroneous conclusion.

17 April 2023

General Court finds no risk of confusion between pharma marks containing ‘brez’/‘breez’ element

The General Court underlined the particularly high level of attention of the relevant public when it comes to medicines that have a direct impact on their health.

03 April 2023

International trademark applications drop steepest amount since 2009 financial crash

New data from WIPO reveals a significant drop in international trademark applications last year, but closer analysis offers optimism for the long-term outlook.

28 February 2023

Five minutes with… The Pharmaceutical Security Institute

WTR sits down with PSI’s Asia-Pacific regional director Ramesh Raj Kishore to look back at the organisation’s journey and forward into the future.

31 January 2023

USPTO trends and top filers: FY2022

Featured in Trademark register tracker

Our annual assessment of the US brand landscape reveals the top filers and representatives, volatile application trends, and much more.

26 January 2023

Clearer guidance on parallel imports of medicinal products

The CJEU’s decision in this case - together with the other decisions issued on 17 November 2022 - provides important guidance for trademark owners and parallel importers in the pharmaceutical industry.

10 January 2023

Novartis succeeds via UKIPO’s critique of VESIQUE

This case shows that it is reasonable for a party to doubt the merits of a preliminary indication issued by the UKIPO when it is not in its favour.

04 January 2023

Unlock unlimited access to all WTR content